SEC Form 3 filed by new insider Delaney Brendan
$BYSI
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 12/31/2024 |
3. Issuer Name and Ticker or Trading Symbol
BeyondSpring Inc. [ BYSI ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Options (right to buy) | (1) | 07/07/2031 | Ordinary Shares | 20,000 | $9.62(1) | D | |
| Stock Options (right to buy) | (2) | 01/01/2032 | Ordinary Shares | 5,000 | $4.53(2) | D | |
| Stock Options (right to buy) | (3) | 03/07/2032 | Ordinary Shares | 10,000 | $1.99(3) | D | |
| Stock Options (right to buy) | (4) | 02/10/2033 | Ordinary Shares | 15,000 | $2.68(4) | D | |
| Stock Options (right to buy) | (5) | 05/08/2033 | Ordinary Shares | 25,000 | $0.9835(5) | D | |
| Stock Options (right to buy) | (6) | 12/18/2033 | Ordinary Shares | 14,906 | $0.99(6) | D | |
| Stock Options (right to buy) | (7) | 01/01/2034 | Ordinary Shares | 10,000 | $0.9(7) | D | |
| Explanation of Responses: |
| 1. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All 20,000 stock options are fully vested and exercisable. |
| 2. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All 5,000 stock options are fully vested and exercisable. |
| 3. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All 10,000 stock options are fully vested and exercisable. |
| 4. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All 15,000 stock options are fully vested and exercisable. |
| 5. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All 25,000 stock options are fully vested and exercisable. |
| 6. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All 14,906 stock options are fully vested and exercisable. |
| 7. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. None of the stock options have become fully vested and exercisable. 10,000 of the stock options will vest on January 1, 2025. |
| Remarks: |
| As the Company no longer qualifies as a foreign private issuer, effective January 1, 2025, the Company's officers, directors, and principal shareholders are subject to Section 16 of the Securities Exchange Act of 1934 ("Exchange Act"). Previously, the Company determined that it qualified as a foreign private issuer under the Exchange Act. |
| /s/ Brendan Delaney | 12/31/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||